Clinical Trial

Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia

Study acronym: DC-CAP
Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
Aim: Demonstrate the equivalent efficacy and superior safety of Ceftriaxone 1 gram daily compared with Ceftriaxone 2 grams daily among hospitalized patients with community-acquired pneumonia who are not admitted to the intensive care unit.\<p\> Hypothesis: Among hospitalized patients outside of the intensive care unit with community-acquired pneumonia who are prescribed Ceftriaxone, a dosage of 1 gram daily will be associated with an equivalent rate of clinical cure and fewer adverse events than a dosage of 2 grams daily.
Trial Details
NCT Number NCT07537413
Lead Sponsor University of Maryland, Baltimore
Conditions Community Acquired Pneumonia (CAP)
Enrollment 430 participants
Start Date 2026-09-01
Primary Completion 2027-08-31 (estimated)
Study Completion 2028-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-04-17